Biomarker Consortium launches
This article was originally published in The Gray Sheet
Executive SummaryThe American College of Radiology Imaging Network's (ACRIN) planned clinical trial exploring the use of fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate non-Hodgkins lymphoma and lung cancer patients' response to therapy is the first project supported by the Biomarker Consortium, a newly formed research partnership between the Foundation for the National Institutes of Health, NIH, FDA, CMS and industry and patient groups, according to an Oct. 5 release. The consortium will identify and validate new biological markers to advance the science of personalized medicine. "Imaging tests such as PET scanning can potentially reduce both suffering and cost for cancer patients by providing better selection of appropriate treatment and determining earlier ... whether treatment will be effective," ACRIN explains. Depression and diabetes are further areas of prospective study cited by the consortium...
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.